• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Vacuum assisted breast biopsy (VAB) excision of subcentimeter microcalcifications as an alternative to open biopsy for atypical ductal hyperplasia.真空辅助乳腺活检(VAB)切除亚厘米级微钙化灶作为非典型导管增生开放性活检的替代方法。
Br J Radiol. 2018 May;91(1085):20180003. doi: 10.1259/bjr.20180003. Epub 2018 Feb 23.
2
Stereotactic vacuum-assisted breast biopsy in 268 nonpalpable lesions.268例不可触及病变的立体定向真空辅助乳腺活检
Radiol Med. 2008 Feb;113(1):65-75. doi: 10.1007/s11547-008-0226-0. Epub 2008 Feb 25.
3
Flat epithelial atypia: conservative management of patients without residual microcalcifications post-vacuum-assisted breast biopsy.扁平上皮异型增生:真空辅助乳腺活检后无残留微钙化患者的保守治疗
Br J Radiol. 2018 Jan;91(1081):20170484. doi: 10.1259/bjr.20170484. Epub 2017 Nov 9.
4
Vacuum-assisted biopsy diagnosis of atypical ductal hyperplasia and patient management.真空辅助活检诊断非典型导管增生及患者管理。
Radiol Med. 2011 Mar;116(2):276-91. doi: 10.1007/s11547-011-0626-9. Epub 2011 Jan 12.
5
Atypical ductal hyperplasia diagnosed at 11-gauge vacuum-assisted breast biopsy performed on suspicious clustered microcalcifications: could patients without residual microcalcifications be managed conservatively?在对可疑簇状微钙化灶进行 11 号空心针真空辅助乳腺活检时诊断出非典型导管增生:没有残留微钙化灶的患者能否保守治疗?
AJR Am J Roentgenol. 2011 Oct;197(4):1012-8. doi: 10.2214/AJR.11.6588.
6
[Stereotactic vacuum core biopsy of clustered microcalcifications classified as B1-RADS 3].[对分类为B1-RADS 3的簇状微钙化灶进行立体定向真空芯针活检]
Rofo. 2001 Aug;173(8):696-701. doi: 10.1055/s-2001-16398.
7
Atypical ductal hyperplasia diagnosis by directional vacuum-assisted stereotactic biopsy of breast microcalcifications. Considerations for surgical excision.通过乳腺微钙化的定向真空辅助立体定向活检诊断非典型导管增生。手术切除的注意事项。
Am J Clin Pathol. 2003 Feb;119(2):248-53. doi: 10.1309/0GYV-4F2L-LJAV-4GFN.
8
Accuracy of percutaneous core biopsy of isolated breast microcalcifications identified by mammography. Experience with a vacuum-assisted large-core biopsy device.乳腺钼靶检查发现的孤立性乳腺微钙化灶经皮芯针活检的准确性。真空辅助大芯针活检装置的经验。
Radiol Med. 2003 Oct;106(4):313-9.
9
Risk of upgrade of atypical ductal hyperplasia after stereotactic breast biopsy: effects of number of foci and complete removal of calcifications.立体定向乳腺活检后非典型导管增生升级的风险:病灶数量和钙化完全切除的影响。
Radiology. 2010 Jun;255(3):723-30. doi: 10.1148/radiol.09091406. Epub 2010 Feb 19.
10
[Breast calcifications with percutaneous vacuum-assisted biopsy diagnosis of malignancy or atypical hyerplasia: correlations with surgical findings].经皮真空辅助活检诊断为恶性或非典型增生的乳腺钙化:与手术结果的相关性
Pathologica. 2002 Dec;94(6):299-305. doi: 10.1007/s102420200053.

引用本文的文献

1
Influence of Complete Lesion Removal During Vacuum-Assisted Breast Biopsy on the Upgrade Rate of B3 Lesions Presenting as Microcalcifications.真空辅助乳腺活检时完全切除病变对以微钙化形式出现的B3级病变升级率的影响。
J Clin Med. 2025 Feb 24;14(5):1513. doi: 10.3390/jcm14051513.
2
Atypical ductal or lobular hyperplasia, lobular carcinoma in-situ, flat epithelial atypia, and future risk of developing breast cancer: Systematic review and meta-analysis.非典型导管或小叶增生、小叶原位癌、扁平上皮不典型增生,以及未来发生乳腺癌的风险:系统评价和荟萃分析。
Breast. 2024 Dec;78:103807. doi: 10.1016/j.breast.2024.103807. Epub 2024 Sep 11.
3
Determination of Factors Associated with Upstage in Atypical Ductal Hyperplasia to Identify Low-Risk Patients Where Active Surveillance May be an Alternative.确定与非典型导管增生升级相关的因素,以识别低风险患者,这些患者可能可以选择主动监测。
Ann Surg Oncol. 2024 May;31(5):3177-3185. doi: 10.1245/s10434-024-15041-1. Epub 2024 Feb 22.
4
Long-Term Follow-Up of High-Risk Breast Lesions at Vacuum-Assisted Biopsy without Subsequent Surgical Resection.真空辅助活检后未进行后续手术切除的高危乳腺病变的长期随访
Breast Care (Basel). 2024 Feb;19(1):62-72. doi: 10.1159/000533673. Epub 2023 Sep 7.
5
Breast Lesions of Uncertain Malignant Potential (B3) and the Risk of Breast Cancer Development: A Long-Term Follow-Up Study.具有不确定恶性潜能的乳腺病变(B3)与乳腺癌发生风险:一项长期随访研究
Cancers (Basel). 2023 Jul 6;15(13):3521. doi: 10.3390/cancers15133521.
6
Implementation of vacuum-assisted excision as a management option for benign and high-risk breast lesions.真空辅助切除在良性和高危乳腺病变治疗中的应用。
Br J Radiol. 2023 Jul;96(1147):20220776. doi: 10.1259/bjr.20220776. Epub 2023 May 12.
7
Circulating microRNA Biomarker for Detecting Breast Cancer in High-Risk Benign Breast Tumors.循环 microRNA 生物标志物可用于检测高风险良性乳腺肿瘤中的乳腺癌。
Int J Mol Sci. 2023 Apr 20;24(8):7553. doi: 10.3390/ijms24087553.
8
Outcomes of high-risk breast lesions diagnosed using image-guided core needle biopsy: results from a multicenter retrospective study.采用影像引导下核心针活检诊断的高危乳腺病变的结果:一项多中心回顾性研究的结果。
Diagn Interv Radiol. 2023 Jul 20;29(4):579-587. doi: 10.4274/dir.2022.221790. Epub 2023 Jan 9.
9
High-Risk Breast Lesions Diagnosed by Ultrasound-Guided Vacuum-Assisted Excision.超声引导下真空辅助切除诊断的高危乳腺病变
World J Surg. 2023 May;47(5):1247-1252. doi: 10.1007/s00268-023-06930-9. Epub 2023 Feb 8.
10
Complete Surgical Excision Is Necessary following Vacuum-Assisted Biopsy for Breast Cancer.乳腺癌真空辅助活检后必须进行完整的外科切除。
Curr Oncol. 2022 Nov 30;29(12):9357-9364. doi: 10.3390/curroncol29120734.

本文引用的文献

1
Atypical ductal hyperplasia: Our experience in the management and long term clinical follow-up in 71 patients.不典型导管增生:71 例患者的处理及长期临床随访经验。
Breast. 2018 Feb;37:1-5. doi: 10.1016/j.breast.2017.10.003. Epub 2017 Oct 12.
2
First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).首届乳腺不确定恶性潜能病变(B3病变)国际共识会议
Breast Cancer Res Treat. 2016 Sep;159(2):203-13. doi: 10.1007/s10549-016-3935-4. Epub 2016 Aug 13.
3
Positive predictive value of breast lesions of uncertain malignant potential (B3): Can we identify high risk patients? The value of a multidisciplinary team and implications in the surgical treatment.具有不确定恶性潜能的乳腺病变(B3)的阳性预测值:我们能否识别高危患者?多学科团队的价值及对手术治疗的影响。
Surg Oncol. 2016 Jun;25(2):119-22. doi: 10.1016/j.suronc.2016.04.002. Epub 2016 Apr 13.
4
Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies.乳腺粗针活检中非典型导管增生和小叶原位癌的长期临床随访
Pathology. 2016 Jan;48(1):25-9. doi: 10.1016/j.pathol.2015.11.015. Epub 2015 Dec 14.
5
Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up.对低级别导管原位癌自然病史的持续观察再次证实,即使经过30多年的随访,其仍有局部复发的倾向。
Mod Pathol. 2015 May;28(5):662-9. doi: 10.1038/modpathol.2014.141. Epub 2014 Dec 12.
6
Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study.通过其自然病史了解非典型增生的癌前潜能:一项纵向队列研究。
Cancer Prev Res (Phila). 2014 Feb;7(2):211-7. doi: 10.1158/1940-6207.CAPR-13-0222. Epub 2014 Jan 30.
7
Atypical ductal hyperplasia on core biopsy: an automatic trigger for excisional biopsy?核心活检中的非典型导管增生:是否是切除活检的自动触发因素?
Ann Surg Oncol. 2012 Oct;19(10):3264-9. doi: 10.1245/s10434-012-2575-0. Epub 2012 Aug 10.
8
Scoring to predict the possibility of upgrades to malignancy in atypical ductal hyperplasia diagnosed by an 11-gauge vacuum-assisted biopsy device: an external validation study.评分系统预测 11 号空芯针活检诊断的非典型导管增生发生恶性转化的可能性:一项外部验证研究。
Eur J Cancer. 2012 Jan;48(1):30-6. doi: 10.1016/j.ejca.2011.08.011. Epub 2011 Nov 17.
9
Atypical ductal hyperplasia diagnosed at 11-gauge vacuum-assisted breast biopsy performed on suspicious clustered microcalcifications: could patients without residual microcalcifications be managed conservatively?在对可疑簇状微钙化灶进行 11 号空心针真空辅助乳腺活检时诊断出非典型导管增生:没有残留微钙化灶的患者能否保守治疗?
AJR Am J Roentgenol. 2011 Oct;197(4):1012-8. doi: 10.2214/AJR.11.6588.
10
The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysis.家族史和组织学分层对良性乳腺疾病女性乳腺癌风险的影响:一项荟萃分析。
J Cancer Res Clin Oncol. 2011 Jul;137(7):1053-60. doi: 10.1007/s00432-011-0979-z. Epub 2011 Apr 17.

真空辅助乳腺活检(VAB)切除亚厘米级微钙化灶作为非典型导管增生开放性活检的替代方法。

Vacuum assisted breast biopsy (VAB) excision of subcentimeter microcalcifications as an alternative to open biopsy for atypical ductal hyperplasia.

作者信息

Schiaffino Simone, Massone Elena, Gristina Licia, Fregatti Piero, Rescinito Giuseppe, Villa Alessandro, Friedman Daniele, Calabrese Massimo

机构信息

1 Department of Radiology, University of Genoa , Genoa , Italy.

2 Department of Surgery, Policlinico San Martino , Genoa , Italy.

出版信息

Br J Radiol. 2018 May;91(1085):20180003. doi: 10.1259/bjr.20180003. Epub 2018 Feb 23.

DOI:10.1259/bjr.20180003
PMID:29451396
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6190792/
Abstract

OBJECTIVE

Atypical ductal hyperplasia (ADH) is a proliferative lesion associated with a variable increased risk of breast malignancy, but the management of the patients is still not completely defined, with mandatory surgical excision in most cases. To report the results of the conservative management with mammographic checks of patients with ADH diagnosed by vacuum assisted breast biopsy (VAB), without residual calcifications.

METHODS

The authors accessed the institutional database of radiological, surgical and pathological anatomy. Inclusion criteria were: ADH diagnosed by VAB on a single group of microcalcifications, without residual post-procedure; follow-up at least of 12 months. Exclusion criteria were the presence of personal history of breast cancer or other high-risk lesions; association with other synchronous lesions, both more and less advanced proliferative lesions.

RESULTS

The 65 included patients were all females, with age range of 40-79 years (mean 54 years). The maximum diameter range of the groups of microcalcifications was 4-11 mm (mean 6.2 mm), all classified as BI-RADS 4b (Breast Imaging Reporting and Data System 4b) and defined as fine pleomorphic in 29 cases (45%) or amorphous in 36 cases (55%). The range of follow-up length was 12-156 months (mean 67 months). Only one patients developed new microcalcifications, in the same breast, 48 months after and 15 mm from the first VAB, interpreted as low-grade ductal carcinoma in situ (DCIS) at surgical excision.

CONCLUSION

These results could justify the conservative management, in a selected group of patients, being the malignancy rate lower than 2%, considered in the literature as the "probably benign" definition. Advances in knowledge: Increasing the length of follow-up of selected patients conservatively managed can improve the management of ADH cases.

摘要

目的

不典型导管增生(ADH)是一种与乳腺癌风险不同程度增加相关的增殖性病变,但对患者的管理仍未完全明确,大多数情况下需进行手术切除。报告经真空辅助乳腺活检(VAB)诊断为ADH且无残留钙化的患者通过乳腺钼靶检查进行保守治疗的结果。

方法

作者查阅了放射学、外科学和病理解剖学的机构数据库。纳入标准为:经VAB在一组微钙化灶上诊断为ADH,术后无残留;随访至少12个月。排除标准为有乳腺癌个人史或其他高危病变;与其他同步病变相关,包括更高级别和较低级别增殖性病变。

结果

纳入的65例患者均为女性,年龄范围40 - 79岁(平均54岁)。微钙化灶组的最大直径范围为4 - 11毫米(平均6.2毫米),均分类为乳腺影像报告和数据系统(BI-RADS)4b级,其中29例(45%)为细多形性,36例(55%)为无定形。随访时间范围为12 - 156个月(平均67个月)。仅1例患者在首次VAB后48个月,距首次VAB 15毫米处同侧乳房出现新的微钙化灶,手术切除时被解释为低级别导管原位癌(DCIS)。

结论

这些结果可以证明在特定患者群体中进行保守治疗是合理的,因为恶性率低于2%,在文献中被视为“可能良性”的定义。知识进展:延长对保守治疗的特定患者的随访时间可以改善ADH病例的管理。